Breaking News Instant updates and real-time market news.

GOOS

Canada Goose

$35.02

-0.41 (-1.16%)

, KHC

Kraft Heinz

$27.20

-0.21 (-0.77%)

10:04
05/31/19
05/31
10:04
05/31/19
10:04

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Canada Goose (GOOS) upgraded to Buy from Neutral at Goldman Sach with analyst Alexandra Walvis saying she believes the company's fundamentals are "still strong" and the weakness in Q4 was driven in part by strategic changes. 2. Kraft Heinz (KHC) upgraded to Neutral from Underweight at Piper Jaffray with analyst Michael Lavery saying he believes the risks appear to be reflected in the stock's current valuation. 3. Molina Healthcare (MOH) upgraded to Outperform from Market Perform at Wells Fargo with analyst Peter Costa saying management highlighted the long-term sustainability of margins and growth at analyst day, which he thinks should be attainable if Molina can avoid losing ground in upcoming contract rebids. 4. Uber (UBER) upgraded to Overweight from Neutral at Atlantic Equities with analyst James Cordwell saying the ridehailing competitive environment is becoming "increasingly benign" while Uber shares have become more attractively valued. 5. Century Communities (CCS) upgraded to Outperform from Neutral at Wedbush with analyst Jay McCanless saying that based on the firm's recent management meetings, he estimates 85% of the company's collective business is targeted to affordable price points suggesting the company should be well positioned to meet that demand. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

GOOS

Canada Goose

$35.02

-0.41 (-1.16%)

KHC

Kraft Heinz

$27.20

-0.21 (-0.77%)

MOH

Molina Healthcare

$138.26

3.51 (2.60%)

UBER

Uber

$40.11

0.355 (0.89%)

CCS

Century Communities

$26.95

0.33 (1.24%)

GOOS Canada Goose
$35.02

-0.41 (-1.16%)

05/31/19
GSCO
05/31/19
UPGRADE
Target $47
GSCO
Buy
Goldman upgrades Canada Goose to Buy, says stock 'compelling' after selloff
Goldman Sachs analyst Alexandra Walvis upgraded Canada Goose Holdings to Buy from Neutral while lowering her price target for the shares to $47 from $65. The stock closed yesterday up $1.55 to $35.44 after a big selloff on Wednesday. In fiscal Q4, Canada Goose's direct-to-consumer sales growth slowed from the elevated growth rates experienced earlier in the year and missed consensus estimates, Walvis tells investors in a research note. While acknowledging that a "high multiple" stock should experience a "significant de-rating" in response to a sales miss, the analyst believes the company's fundamentals are "still strong." The weakness in Q4 was driven in part by strategic changes as the company shipped product and set floors earlier to take advantage of early season demand, says the analyst. Going forward, Walvis sees "several compelling growth drivers" for Canada Goose. As a result, she finds the stock's risk/reward "compelling" at current share levels.
05/30/19
ADAM
05/30/19
NO CHANGE
ADAM
Buy
Canada Goose selloff belies long growth runway, says Canaccord
Canaccord analyst Camilo Lyon noted Canada Goose sold off following its Q4 results and he believes the company made a mistake bringing out the spring floor set too early during the quarter, despite continued demand for cold-weather outerwear across the US and Canada. He believes the merchandising decision is not reflective of softening demand, nor is it representative of the future growth prospects. Lyon reiterated his Buy rating and lowered his price target to C$82 from C$95 on Canada Goose shares.
05/30/19
05/30/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Verizon (VZ) downgraded to Neutral from Buy at UBS with analyst John Hodulik saying with the valuation back in-line with historical levels and more difficult comps ahead, Verizon's risk/reward is more balanced at current share levels. 2. Canada Goose (GOOS) downgraded to Neutral from Buy at BofA/Merrill with analyst Robert Ohmes saying the Direct-to-Consumer, or DTC, slowdown indicates saturation risk and warrants a lower multiple. 3. ViaSat (VSAT) downgraded to Market Perform from Outperform at Raymond James with analyst Rick Prentiss saying shares are up 55% year-to-date, reflecting good news, and expects an increase in R&D and capex from VS-3 satellite builds and deployments, expanding LatAm operations, and acquiring STCs. 4. Teva (TEVA) double downgraded to Underperform from Buy at BofA/Merrill with analyst Jason Gerberry saying Teva's financial downside to ongoing opioid litigation is difficult to gauge and the highly fragmented nature of the lawsuits makes a global settlement unlikely. 5. Toll Brothers (TOL) downgraded to Market Perform from Outperform at Raymond James with analyst Buck Horne saying he is "concerned" that shares will be range-bound near-term due to reduced estimates, a lack of upcoming catalysts, and lingering West Coast issues. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/19
GSCO
05/31/19
UPGRADE
GSCO
Buy
Canada Goose upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Alexandra Walvis upgraded Canada Goose Holdings to Buy from Neutral saying the risk/reward is "compelling" following this week's pullback in the shares. The company's growth algorithm is intact, says Walvis.
KHC Kraft Heinz
$27.20

-0.21 (-0.77%)

04/24/19
04/24/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Harley-Davidson (HOG) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying he views Harley as the "worst positioned" within his Powersports coverage given its concentration in a "secularly declining" motorcycle market. 2. TowerJazz (TSEM) downgraded to Neutral from Outperform at Credit Suisse with analyst Quang Tung Le saying to reflect ongoing weakness at the company's "key" radio frequency and power customers along with revised three- year deal extension with Panasonic, the analyst reduced his sales estimates. 3. Marriott (MAR) downgraded to In Line from Outperform at Evercore ISI with analyst Rich Hightower saying approaching Q1 earnings season, the analyst finds himself "incrementally negative" on hotel stocks overall - and even more so with respect to the C-Corps than the REITs - given the sector's substantial recent outperformance against the relevant benchmarks, coupled with no obvious shift in fundamentals over the last 60-90 days. 4. Kraft Heinz (KHC) downgraded to Underweight from Neutral at Piper Jaffray with analyst Michael Lavery saying expectations for the company's 2020 earnings are likely too high as it plans divestitures of underperforming businesses, which could be 20c-30c dilutive on a per share basis. 5. Hyatt (H) and Hilton (HLT) downgraded to Market Perform from Outperform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/19
PIPR
05/31/19
UPGRADE
PIPR
Neutral
Kraft Heinz upgraded to Neutral from Underweight at Piper Jaffray
05/31/19
PIPR
05/31/19
UPGRADE
Target $31
PIPR
Neutral
Piper upgrades Kraft Heinz to Neutral, says risks priced in
Piper Jaffray analyst Michael Lavery upgraded Kraft Heinz to Neutral from Underweight with an unchanged price target of $31. The analyst, who remains curious on the outlook for Kraft Heinz and its ability to build brand equity in a way that can drive sustainable organic growth, believes the risks appear to be reflected in the stock's current valuation. A new CEO is the right move, but he needs incremental brand spending to rejuvenate the company's "dusty brands," says the analyst.
05/30/19
FBCO
05/30/19
NO CHANGE
Target $26
FBCO
Underperform
Kraft Heinz price target lowered to $26 from $33 at Credit Suisse
Credit Suisse analyst Robert Moskow lowered his price target for Kraft Heinz to $26 from $33 on below management guidance due to the possibility that the SEC's investigation into the company will continue to reveal breakdowns in its internal controls and negatively impact the forward outlook. The analyst believes there is also "significant uncertainty" related to potential dilution from divestitures and reinvestment needs. Moskow reiterates an Underperform rating on the stock.
MOH Molina Healthcare
$138.26

3.51 (2.60%)

05/31/19
WELS
05/31/19
UPGRADE
WELS
Outperform
Molina Healthcare upgraded to Outperform from Market Perform at Wells Fargo
05/31/19
LEHM
05/31/19
NO CHANGE
Target $149
LEHM
Equal Weight
Molina Healthcare price target raised to $149 from $140 at Barclays
Barclays analyst Steve Valiquette raised his price target for Molina Healthcare to $149 from $140 saying the company at its investor day laid out a blueprint for "impressive" long-term growth from the "already improved" current earnings base. Molina's three-to-five year long-term guidance includes "strong" 10%-12% premium growth, Valiquette tells investors in a research note. He points out the company also introduced 12%-15% long-term earnings growth. The analyst keeps an Equal Weight rating on the shares.
05/31/19
WELS
05/31/19
UPGRADE
Target $177
WELS
Outperform
Molina Healthcare upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Peter Costa upgraded Molina Healthcare to Outperform from Market Perform and raised his price target to $177 from $139 following the company's analyst day, saying management management highlighted the long-term sustainability of margins and growth which Costa thinks should be attainable if Molina can avoid losing ground in upcoming contract rebids, including Texas, and if it can push its in-market growth strategy at the expense of its managed care competitors. While some found the high margin guidance to be a concern, Costa tells investors in a research note that he believes the low new business win guidance of $1.5B-2.B over 3-5 years to be supportive of the long-term Medicaid after-tax margin guide of 2.8%-3.2%.
05/16/19
COWN
05/16/19
NO CHANGE
COWN
Move lower in managed care stocks appears overdone, says Cowen
Cowen analyst Charles Rhyee lowered his target multiple for the managed care group slightly from recent historical levels, but said he believes the recent weakness in the space on concerns around "Medicare for All," the rebate rule and the Texas ACA decision appears overdone. The discount for managed care stocks relative to the broader market has risen to a multi-year high, but he argues that underlying market fundamentals are stronger than in the pre-ACA era and Rhyee contends that there is "still plenty of growth left" in the managed care space, particularly in government-sponsored business. Stocks in the group include Anthem (ANTM), Cigna (CI), Centene (CNC), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
UBER Uber
$40.11

0.355 (0.89%)

05/31/19
JPMS
05/31/19
NO CHANGE
Target $86
JPMS
Overweight
JPMorgan says buy Lyft as shares offer 50% potential upside
After hosting investor meetings with management, JPMorgan analyst Doug Anmuth recommends buying shares of Lyft (LYFT) on the "increasingly rational" ridesharing industry as well as the company's improving profitability. Management's overall tone was very confident around the easing of the competitive environment in U.S. ridesharing, core ridesharing losses improving, ongoing leverage in insurance costs, and the "high-growth, high-margin" revenue opportunities in Lyft Business, Anmuth tells investors in a research note. Further and importantly, on its earnings call last night, Uber (UBER) echoed Lyft's comments on the more favorable operating environment in the U.S., adds the analyst. He keeps an Overweight rating on Lyft with an $86 price target, suggesting 50% potential upside. The stock closed yesterday down $1.43 to $54.83.
05/31/19
ATLE
05/31/19
UPGRADE
Target $52
ATLE
Overweight
Atlantic upgrades Uber on 'increasingly benign' competitive environment
Atlantic Equities analyst James Cordwell upgraded Uber Technologies to Overweight from Neutral while lowering his price target for the shares to $52 from $55. The stock closed yesterday down 14c to $39.80. The ridehailing competitive environment is becoming "increasingly benign" while Uber shares have become more attractively valued, Cordwell tells investors in a research note. The analyst expects a better competitive environment to drive accelerating revenue growth and moderating segment losses across fiscal 2019. Further, a new Uber Eats fee structure should augment the company's food delivery economics while enabling "rapid" bookings growth, Cordwell tells investors in a research note.
05/31/19
WEDB
05/31/19
NO CHANGE
Target $65
WEDB
Outperform
Uber's Q1 'an important step,' says Wedbush
Wedbush analyst Ygal Arounian reiterated an Outperform rating and $65 price target on Uber following the comany's Q1 results, saying the report was an "important step" for the company as investors needed a bridge between near-term headwinds and the long-term vision working. Additionally, Arounian says he feels that the results addressed many concerns investors had been seeking clarity on, despite not giving revenue or EBITDA guidance for the full year.
05/31/19
DADA
05/31/19
NO CHANGE
Target $46
DADA
Neutral
Uber price target lowered to $46 from $53 at DA Davidson
DA Davidson analyst Tom White lowered his price target on Uber (UBER) to $46 and kept his Neutral rating after its Q1 results revealed "few surprises". The analyst notes that although the management was more positive on moderating competition, as Uber and Lyft (LYFT) start to compete "more around brand and product" rather than price, he does not expect major changes in the buy-side estimates on the stock. White notes that his new price target assumes a "more conservative" 4.1-time multiple on enterprise value relative to his expected FY20 sales.
CCS Century Communities
$26.95

0.33 (1.24%)

05/31/19
WEDB
05/31/19
UPGRADE
Target $33
WEDB
Outperform
Century Communities upgraded to Outperform from Neutral at Wedbush
Wedbush analyst Jay McCanless upgraded Century Communities to Outperform from Neutral and raised his price target to $33 from $39, saying that based on the firm's recent management meetings, he estimates 85% of the company's collective business is targeted to affordable price points, suggesting the company should be well positioned to meet that demand. McCanless sees catalysts as the comapny's focus on the affordable products, increasing first-time buyer demand in national statistics and a "manageable" exposure to markets on the Pacific coast.
05/31/19
WEDB
05/31/19
UPGRADE
WEDB
Outperform
Century Communities upgraded to Outperform from Neutral at Wedbush
03/07/19
ZELM
03/07/19
UPGRADE
ZELM
Buy
Century Communities upgraded to Buy from Hold at Zelman
02/08/19
WEDB
02/08/19
DOWNGRADE
Target $24
WEDB
Neutral
Century Communities downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Jay McCanless downgraded Century Communities to Neutral from Outperform and lowered his price target to $24 from $26. In a research note to investors, McCanless says that while the negative y/y order growth in Century's newly acquired unit, Wade Jurney Homes, may prove short-lived as Century adjusts the strategy, he is concerned that demand for the WJ product has not been as robust as he expected especially given WJ's ultra-low price approach. In light of that weakness and the Q4 negative order growth for Century's legacy businesses excluding Texas, he is stepping to the sidelines.

TODAY'S FREE FLY STORIES

ERYP

Erytech Pharma

$6.69

(0.00%)

17:33
06/24/19
06/24
17:33
06/24/19
17:33
Hot Stocks
Erytech Pharma announces strategic collaboration with SQZ Biotechnologies »

ERYTECH Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$359.98

0.555 (0.15%)

17:33
06/24/19
06/24
17:33
06/24/19
17:33
Hot Stocks
Lockheed Martin awarded $561.80M Army contract »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCO

The Medicines Co.

$35.38

-1.01 (-2.78%)

17:30
06/24/19
06/24
17:30
06/24/19
17:30
Syndicate
The Medicines Co. files to sell $150M of common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHTLY

Metcash

$0.00

(0.00%)

17:30
06/24/19
06/24
17:30
06/24/19
17:30
Downgrade
Metcash rating change  »

Metcash downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

, LLL

L3 Technologies

$256.30

(0.00%)

17:28
06/24/19
06/24
17:28
06/24/19
17:28
Hot Stocks
S&P announces changes to S&P 400, 500, 600 indices »

S&P Dow Jones Indices…

MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

LLL

L3 Technologies

$256.30

(0.00%)

AAXN

Axon

$73.22

-0.12 (-0.16%)

MLAB

Mesa Labs

$227.44

-3.4 (-1.47%)

HRS

Harris

$197.28

-0.07 (-0.04%)

USNA

Usana

$72.41

-0.58 (-0.79%)

LION

Fidelity Southern

$30.18

-0.06 (-0.20%)

ABCB

Ameris Bancorp

$37.76

(0.00%)

XNCR

Xencor

$33.86

-1.31 (-3.72%)

HF

HFF Inc.

$45.25

-0.29 (-0.64%)

JLL

Jones Lang LaSalle

$137.43

-2.075 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 06

    Aug

  • 26

    Aug

TMSR

TMSR Holding

$1.67

(0.00%)

17:28
06/24/19
06/24
17:28
06/24/19
17:28
Syndicate
Breaking Syndicate news story on TMSR Holding »

TMSR Holding files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCO

The Medicines Co.

$35.38

-1.01 (-2.78%)

17:27
06/24/19
06/24
17:27
06/24/19
17:27
Syndicate
Breaking Syndicate news story on The Medicines Co. »

The Medicines Co. files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XNCR

Xencor

$33.86

-1.31 (-3.72%)

, HF

HFF Inc.

$45.25

-0.29 (-0.64%)

17:22
06/24/19
06/24
17:22
06/24/19
17:22
Hot Stocks
Xencor to replace HFF Inc. in S&P 600 at open on 7/2 »

Jones Lang LaSalle (JLL)…

XNCR

Xencor

$33.86

-1.31 (-3.72%)

HF

HFF Inc.

$45.25

-0.29 (-0.64%)

JLL

Jones Lang LaSalle

$137.43

-2.075 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 06

    Aug

  • 26

    Aug

USNA

Usana

$72.41

-0.58 (-0.79%)

, LION

Fidelity Southern

$30.18

-0.06 (-0.20%)

17:20
06/24/19
06/24
17:20
06/24/19
17:20
Hot Stocks
Usana to replace Fidelity Southern in S&P 600 at open on 7/1 »

Ameris Bancorp (ABCB) is…

USNA

Usana

$72.41

-0.58 (-0.79%)

LION

Fidelity Southern

$30.18

-0.06 (-0.20%)

ABCB

Ameris Bancorp

$37.76

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLAB

Mesa Labs

$227.44

-3.4 (-1.47%)

, AAXN

Axon

$73.22

-0.12 (-0.16%)

17:19
06/24/19
06/24
17:19
06/24/19
17:19
Hot Stocks
Breaking Hot Stocks news story on Mesa Labs, Axon »

Mesa Labs to replace Axon…

MLAB

Mesa Labs

$227.44

-3.4 (-1.47%)

AAXN

Axon

$73.22

-0.12 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAXN

Axon

$73.22

-0.12 (-0.16%)

, MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

17:18
06/24/19
06/24
17:18
06/24/19
17:18
Hot Stocks
Breaking Hot Stocks news story on Axon, MarketAxess »

Axon to replace…

AAXN

Axon

$73.22

-0.12 (-0.16%)

MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

, LLL

L3 Technologies

$256.30

(0.00%)

17:18
06/24/19
06/24
17:18
06/24/19
17:18
Hot Stocks
MarketAxess to replace L3 Technologies in S&P 500 at open on 7/1 »

Harris (HRS) is acquiring…

MKTX

MarketAxess

$332.76

-0.24 (-0.07%)

LLL

L3 Technologies

$256.30

(0.00%)

HRS

Harris

$197.28

-0.07 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VGZ

Vista Gold

$0.81

-0.0026 (-0.32%)

17:04
06/24/19
06/24
17:04
06/24/19
17:04
Hot Stocks
Vista Gold CFO Jack Engele to retire, Douglas Tobler to succeed »

Vista Gold is pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$198.60

-0.17 (-0.09%)

17:03
06/24/19
06/24
17:03
06/24/19
17:03
Periodicals
Apple to announce Seattle expansion on Monday, Seattle Times reports »

According to a story by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$15.00

0.07 (0.47%)

, CRWD

Crowdstrike

$67.91

-5.09 (-6.97%)

17:01
06/24/19
06/24
17:01
06/24/19
17:01
Hot Stocks
HP Enterprise appoints Crowdstrike CEO George Kurtz to Board of Directors »

Hewlett Packard…

HPE

HP Enterprise

$15.00

0.07 (0.47%)

CRWD

Crowdstrike

$67.91

-5.09 (-6.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

NGM

NGM Biopharmaceuticals

$13.88

0.1 (0.73%)

17:01
06/24/19
06/24
17:01
06/24/19
17:01
Initiation
NGM Biopharmaceuticals initiated  »

NGM Biopharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda Pharmaceuticals

$13.81

-0.27 (-1.92%)

17:00
06/24/19
06/24
17:00
06/24/19
17:00
Hot Stocks
Armistice Capital reports 6.2% passive stake in Vanda Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

CBAY

CymaBay

$6.76

-0.32 (-4.52%)

16:58
06/24/19
06/24
16:58
06/24/19
16:58
Initiation
CymaBay initiated  »

CymaBay initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PK

Park Hotels & Resorts

$27.47

-0.73 (-2.59%)

16:58
06/24/19
06/24
16:58
06/24/19
16:58
Hot Stocks
Park Hotels & Resorts announces sale of three non-core assets for $166M »

Park Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$79.64

-1.74 (-2.14%)

16:56
06/24/19
06/24
16:56
06/24/19
16:56
Initiation
Intercept initiated  »

Intercept initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$41.15

11.87 (40.54%)

16:48
06/24/19
06/24
16:48
06/24/19
16:48
Syndicate
Krystal Biotech files to sell $100M of common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

GNFT

Genfit

$20.19

-0.02 (-0.10%)

16:40
06/24/19
06/24
16:40
06/24/19
16:40
Hot Stocks
Breaking Hot Stocks news story on Genfit »

Genfit SA (ADS) trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
06/24/19
06/24
16:40
06/24/19
16:40
General news
Fed's Kaplan wants to take more of a wait-and-see approach to policy »

Fed's Kaplan wants…

CHWY

Chewy

$31.52

-0.64 (-1.99%)

16:38
06/24/19
06/24
16:38
06/24/19
16:38
Hot Stocks
Lone Pine Capital reports 6.1% passive stake in Chewy »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$10.00

-0.48 (-4.58%)

16:38
06/24/19
06/24
16:38
06/24/19
16:38
Syndicate
ArQule files to sell common stock, no amount given »

SVB Leerink and RBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.